Millendo Therapeutics to Participate in May Investor Conferences
ANN ARBOR, Mich.--(BUSINESS WIRE)--May 2, 2019--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews at the following healthcare investor conferences:
- 2019 SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on Tuesday, May 7, 2019 in New York, where one-on-one investor meetings will be held.
- 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 10:00 a.m. EST in New York. A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005167/en/
CONTACT: Millendo Investor Contact:
Stern Investor Relations
Millendo Media Contact:
KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Millendo Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 05/02/2019 08:30 AM/DISC: 05/02/2019 08:30 AM